CoChat

The effect of liraglutide on renal function: A randomized clinical trial

von Scholten, Bernt J., Persson, Frederik, Rosenlund, Signe, Hovind, Peter, Faber, Jens, Hansen, Tine W., Rossing, Peter · 2017 · Diabetes, Obesity and Metabolism
Cited by 105

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Aims: Among patients with type 2 diabetes and albuminuria, cardiorenal morbidity and mortality are high despite multifactorial treatment. Short‐term reduction in albuminuria is considered suggestive of long‐term renoprotective effects. We evaluated the renal effects of the glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist liraglutide on top of multifactorial care, including renin‐angiotensin‐system ( RAS )‐inhibition. Materials and methods: Randomized, double‐blind, placebo‐controlled, cross‐over trial including patients with type 2 diabetes and persistent albuminuria (urinary albumin‐to‐creatinine ratio >30 mg/g) and estimated glomerular filtration rate ( eGFR ) ≥30 mL /min/1.73 m 2 . Patients received liraglutide (1.8 mg/d) and matched placebo for 12 weeks in a random order. The primary endpoint was change in 24‐h urinary albumin excretion rate ( UAER ). Results: A total of 32 patients were randomized and 27 completed the study. After placebo treatment, geometric mean ( IQR ) UAER was 199 (81‐531) mg/24‐h, mean ( SD ) measured GFR ( mGFR ) 75 (36) mL /min/1.73 m 2 , 24‐h blood pressure 145/80 (15/8) mm Hg and HbA1c 61 (11) mmol/mol. Liraglutide reduced HbA1c by 8 (95% CI : 5; 11) mmol/mol ( P < .001) and weight by 1.8 (95% CI : 0.2; 3.4) kg ( P = .032) compared to placebo. Furthermore, liraglutide reduced UAER by 32 (95% CI : 7; 50)% ( P = .017) compared with placebo. The change in mGFR was −5 (95% CI : −11; 2) mL /min/1.73 m 2 ( P = .15), and change in 24‐h systolic blood pressure was −5 (95% CI : −10; 0) mm Hg ( P = .07). In multivariate regression models, change in UAER was associated with change in 24‐h systolic blood pressure ( P = .025) but not with change in HbA1c , weight or mGFR ( P ≥ .14), overall model R 2 = .39. Conclusions: Our placebo‐controlled randomized trial suggests that liraglutide has renoprotective effects on top of multifactorial treatment, including RAS ‐inhibition, in patients with type 2 diabetes and albuminuria.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12808

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 105

Metadata

Authors
von Scholten, B. J., Persson, F., Rosenlund, S., Hovind, P., Faber, J., Hansen, T. W., & Rossing, P.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2016-11-21
Volume
19
Issue
2
Pages
239-247
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2537726188
Cited by
105
References
15
FWCI
9.05
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.